BAP1 tumor predisposition syndrome (BAP1-TPDS) is an inherited cancer predisposition disorder caused by pathogenic germline variants in the BAP1 gene. It is inherited in an autosomal dominant pattern and affects a tumor suppressor gene involved in DNA repair, chromatin regulation, and cell cycle control, thereby increasing the risk of developing tumors such as uveal melanoma, mesothelioma, cutaneous melanoma, and renal carcinoma.
BAP1 tumor predisposition syndrome
The BAP1 gene encodes BRCA1-associated protein 1, a nuclear deubiquitinase that participates in essential cellular processes such as DNA repair, chromatin remodeling, transcriptional regulation, cell cycle, differentiation, and apoptosis. Its function as a tumor suppressor contributes to maintaining genome stability and preventing uncontrolled proliferation of cells with accumulated damage. When pathogenic germline variants exist in BAP1, one of the gene copies loses its function. For a tumor to develop, somatic inactivation of the remaining normal copy in a specific tissue is usually necessary, following the "two-hit" model described for tumor suppressor genes. This syndrome is associated with an increased, although variable, risk of tumors with BAP1 inactivation, especially BAP1-inactivated melanocytic tumors (BIMT), uveal melanoma, pleural or peritoneal mesothelioma, cutaneous melanoma, and renal cell carcinoma; basal cell carcinoma, meningioma, and cholangiocarcinoma have also been described in some patients. Inheritance is autosomal dominant, meaning each descendant of a carrier has a 50% chance of inheriting the variant. It is a rare and likely underdiagnosed condition, with incomplete penetrance and significant clinical variability even within the same family.
Symptoms
The syndrome itself does not produce constant symptoms; the manifestations depend on the tumors or lesions that appear, usually in adulthood and often earlier than expected for sporadic tumors. The most characteristic findings include BIMT-type skin lesions, which can present as skin-colored, pink, or brownish papules or nodules, in addition to uveal melanoma, cutaneous melanoma, mesothelioma, and renal carcinoma. The presence of multiple primary tumors, a compatible family history, or multiple skin lesions should suggest a hereditary predisposition associated with BAP1.
Disease management
Management is based on proactive surveillance and early detection of associated tumors. Periodic dermatological follow-up is recommended for skin lesions and melanoma, regular ophthalmological evaluation to detect uveal melanoma, and renal surveillance with imaging tests in experienced centers. Mesothelioma monitoring should be individualized, as the benefit of systematic screening is not fully established. It is also advisable to avoid modifiable risk factors, such as asbestos exposure, smoking, and excessive ultraviolet radiation. There is no treatment that corrects the germline BAP1 variant, but genetic diagnosis allows for personalized surveillance, genetic counseling, and cascade screening of at-risk family members.
Genes analyzed
Bibliography
Rai K, Pilarski R, Cebulla CM, et al. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 2016 Mar;89(3):285-94.
Pilarski R, Byrne L, Carlo MI, et al. BAP1 Tumor Predisposition Syndrome. 2016 Oct 13 [updated 2024 Dec 5]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Lazcano Segura RN, Hoang MP. BAP1 Tumor Predisposition Syndrome. Adv Anat Pathol. 2025 Jul 28.
